The Government is now operating in accordance with the Caretaker Conventions pending the outcome of the 2022 federal election.
The Government is now operating in accordance with the Caretaker Conventions pending the outcome of the 2022 federal election.
Management of the australianclinicaltrials.gov.au website has been transferred from NHMRC to the Commonwealth Department of Health. Disruption to site users as a consequence of this change should be minimal.
Print recordBroad Health Condition Metabolic and Endocrine
Specific Health ConditionNormal metabolism and endocrine development and function
Trial Focus
Treatment
Recruitment statusRecruiting
Anticipated date of first participant enrolment6/02/2008
Anticipated date of last participant enrolment6/02/2008
Phase of TrialPhase 4
Has the study received ethics approval?Approved
Trial summary
We aim to investigate the effects of raloxifene (SERM) in hypogonadal men on the growth hormone system and metabolism.
Key inclusion criteria
Hypogonadism (prostate cancer patients on androgen deprivation therapy for at least 6 months)
Minimum age40 Years
Maximum age80 Years
GenderMales
Can Healthy volunteers participate?No
Key exclusion criteria
Androgen deprivation for less than 6 months, metastasis, cancer in other tissues than prostate, diabetes, kidney and liver disease, deep vein thrombosis
Sponsor Primary Sponsor Type: Hospital
Primary Sponsor Name: Department of Endocrinology, St Vincent's Hospital
Primary Sponsor Address: 390 Victoria St Darlinghurst, NSW 2010
Primary Sponsor Country: Australia
Trial IDACTRN12608000537358
Contact person for information and recruitment
Prof Ken Ho, MD, FRACP, Head of Dept of Endocrinology, St Vincent’s Hospital
Pituitary Research Unit
Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst
2010 NSW
02 9295 8482
02 9295 8481k.ho@garvan.org.au
Australia
